3-溴-4-甲氧基-1H-吡唑并[3,4-d]嘧啶 | 190430-36-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 3-溴-4-甲氧基-1H-吡唑并[3,4-d]嘧啶
• 英文名称: 3-bromo-4-methoxy-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 3-bromo-4-methoxy-2H-pyrazolo[3,4-d]pyrimidine
• CAS: 190430-36-5
• 化学式: C₆H₅BrN₄O
• 分子量: 229.036
• InChiKey: WIGPGRHAXNIUJM-UHFFFAOYSA-N

物化性质

• 沸点：
  325.6±52.0 °C(Predicted)
• 密度：
  2.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  63.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-溴-4-甲氧基-1H-吡唑并[3,4-d]嘧啶 在 氢氧化钾 、 sodium hydride 作用下， 以 乙腈 为溶剂， 反应 1.0h， 生成 2-[2-deoxy-3,5-di-O-(p-toluoyl)-β-D-erythro-pentofuranosyl]-4-methoxy-2H-pyrazolo[3,4-d]pyrimidine
  参考文献：
  名称：

  Unexpected Dehalogenation of 3-Bromopyrazolo[3,4-d]pyrimidine Nucleosides During Nucleobase-Anion Glycosylation

  摘要：

  The anion-glycosylation (KOH, MeCN, TDA-1) of 3-bromopyrazolo[3,4-d]pyrimidines 4a and 4b with 2-deoxy-3,5-di-O-(p-toluoyl)-alpha-D-erythro-pentofuranoysl chloride (5) furnishes the regioisomeric N-1-beta-D-2'-deoxyribonucleosides 6a and 6b together with the dehalogenated N-2-regioisomers 8a and 8b, stereoselectively. The dehalogenation takes place after the glycosylation and results from the sensitivity of the N-2 nucleosides toward aqueous base. An addition/elimination mechanism is suggested for the dehalogenation reaction.

  DOI：

  10.1080/07328319708001351
• 作为产物：
  描述：

  4-甲氧基-1H-吡唑并[3,4-d]嘧啶 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 0.5h， 以75%的产率得到3-溴-4-甲氧基-1H-吡唑并[3,4-d]嘧啶
  参考文献：
  名称：

  Unexpected Dehalogenation of 3-Bromopyrazolo[3,4-d]pyrimidine Nucleosides During Nucleobase-Anion Glycosylation

  摘要：

  The anion-glycosylation (KOH, MeCN, TDA-1) of 3-bromopyrazolo[3,4-d]pyrimidines 4a and 4b with 2-deoxy-3,5-di-O-(p-toluoyl)-alpha-D-erythro-pentofuranoysl chloride (5) furnishes the regioisomeric N-1-beta-D-2'-deoxyribonucleosides 6a and 6b together with the dehalogenated N-2-regioisomers 8a and 8b, stereoselectively. The dehalogenation takes place after the glycosylation and results from the sensitivity of the N-2 nucleosides toward aqueous base. An addition/elimination mechanism is suggested for the dehalogenation reaction.

  DOI：

  10.1080/07328319708001351

文献信息

• Solvent-Controlled, Site-Selective <i>N</i>-Alkylation Reactions of Azolo-Fused Ring Heterocycles at N1-, N2-, and N3-Positions, Including Pyrazolo[3,4-<i>d</i>]pyrimidines, Purines, [1,2,3]Triazolo[4,5]pyridines, and Related Deaza-Compounds
  作者：Brett C. Bookser、Michael I. Weinhouse、Aaron C. Burns、Andrew N. Valiere、Lino J. Valdez、Pawel Stanczak、Jim Na、Arnold L. Rheingold、Curtis E. Moore、Brian Dyck

  DOI：10.1021/acs.joc.8b00540

  日期：2018.6.15

  coordinated to sodium indicated a potential role for the latter reinforcing the N2-selectivity. Limits of selectivity were tested with 26 heterocycles which revealed that N7 was a controlling element directing alkylations to favor N2 for pyrazolo- and N3 for imidazo- and triazolo-fused ring heterocycles when conducted in THF. Use of 1H-detected pulsed field gradient-stimulated echo (PFG-STE) NMR defined

  使用NaHMDS作为碱，在THF中用碘甲烷将4-甲氧基-1 H-吡唑并[3,4- d ]嘧啶（1b）烷基化，选择性地提供了N2-甲基产物4-甲氧基-2-甲基-2 H-吡唑并[3，相对于N1-甲基产物（2b），以8/1的比例存在4- d ]嘧啶（3b）。有趣的是，在DMSO中进行反应使选择性逆转，以提供4/1的N1 / N2甲基化产物比例。产品3b的晶体结构N1和N7与钠配位表明后者可能增强N2选择性。用26个杂环测试了选择性极限，结果表明，当在THF中进行反应时，N7是控制烷基化的控制元素，对于吡唑并环而言，该环对吡唑并环反应有利于N2，对咪唑和三唑并稠合的环杂环则有利于N3。使用1个H-检测脉冲场梯度受激回波（PFG-STE）NMR确定的离子反应性复合物的分子量。该数据和DFT电荷分布计算表明，紧密离子对（CIP）或紧密离子对（TIP）控制THF中的烷基化选择性，而溶剂分离的离子对（SIPs）是DMSO中的反应性物质。
• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Revisiting Pyrazolo[3,4-<i>d</i>]pyrimidine Nucleosides as Anti-<i>Trypanosoma cruzi</i> and Antileishmanial Agents
  作者：Jakob Bouton、Ludmila Ferreira de Almeida Fiuza、Camila Cardoso Santos、Maria Angela Mazzarella、Maria de Nazaré Correia Soeiro、Louis Maes、Izet Karalic、Guy Caljon、Serge Van Calenbergh

  DOI：10.1021/acs.jmedchem.1c00135

  日期：2021.4.8

  for new drug discovery. As both kinetoplastid parasites are incapable of de novo purine synthesis, they depend on purine salvage pathways that allow them to acquire and process purines from the host to meet their demands. Purine nucleoside analogues therefore constitute a logical source of potential antiparasitic agents. Earlier optimization efforts of the natural product tubercidin (7-deazaadenosine)

  恰加斯病和内脏利什曼病是导致世界各地众多死亡的两种被忽视的热带病。对于这两种方法，目前的治疗方法都远远不够，导致对新药发现的持续需求。由于两种运动质体寄生虫均无法进行嘌呤从头合成，因此它们依赖于嘌呤挽救途径，从而使它们能够从宿主处获取和加工嘌呤来满足其需求。因此，嘌呤核苷类似物构成潜在抗寄生虫剂的逻辑来源。天然产物结核菌素（7-脱氮杂腺苷）的早期优化工作涉及对核碱基7位和呋喃核糖3'位的修饰，从而产生了具有强效抗布鲁氏锥虫和抗克鲁氏锥虫的类似物活动。在这项工作中，我们报告了3'-和7-修饰的吡唑并[3,4- d ]嘧啶核苷的设计和合成，并评估了它们作为抗克氏锥虫和抗疟药的潜力。选择了一种化合物在急性恰加斯病小鼠模型中进行体内评估。
• CDK Modulators
  申请人：Bahceci Suleyman

  公开号：US20110201599A1

  公开（公告）日：2011-08-18

  A compound according to Formula I: or a pharmaceutically-acceptable salt thereof, wherein R1, R3, A, B and D are as defined in the specification; pharmaceutical compositions thereof, and methods of use thereof.

  根据公式I的化合物：或其药学上可接受的盐，其中R1，R3，A，B和D如规范中定义;其制药组合物以及使用方法。
• Substituted heteroaryls as inhibitors of the BCL6 BTB domain protein-protein interaction
  申请人：Ontario Institute for Cancer Research (OICR)

  公开号：US11518764B2

  公开（公告）日：2022-12-06

  The present application relates to compounds of Formula I or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及式 I 化合物 或其药学上可接受的盐、溶液剂和/或原药，涉及包含这些化合物或其药学上可接受的盐、溶液剂和/或原药的组合物，以及在治疗可通过抑制与 BCL6 BTB 的相互作用来治疗的疾病、失调或病症（如癌症）中的各种用途。